Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Research on MHC Background and TCR Diversity in Vaccinology"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 3774
Special Issue Editor
Interests: PCR-based MHC typing; swine leukocyte antigen (SLA); TCR diversity; porcine vaccinology; canine and feline lymphomas
Special Issue Information
Tailored vaccine candidate T cell antigens are playing a crucial role in designing and developing promising immunization strategies against e.g., viral infections.
In contrast to traditional vaccines based on attenuated or inactivated pathogens that are often sufficiently immunogenic without added adjuvants, safer protein-based vaccines require adjuvants to induce a protective and long-lasting immune response. Antigen (Ag)-specific CD4 T helper cells play an essential role in the generation and maintenance of long-lasting humoral and cellular immunity and are therefore important vaccine targets. Successful priming and expansion of CD4 T-cell responses require T-cell receptor (TCR) recognition of foreign peptides bound to class II major histocompatibility complex (pMHCII) on the surface of dendritic cells (DCs).
In this context, we would like to encourage and appreciate the submission of recent advancements in providing evidence for the dependence on the MHC background and TCR diversity for the vaccination success to this special issue.
Contributions addressing aspects relevant for designing vaccines against zoonotic or emerging diseases, such as SARS-CoV-2, will also be considered for publication.
Dr. Sabine E. Hammer
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- T cell receptor
- vaccine design